This unprecedented success is due to the development of numerous highly effective HER2-targeting agents capable of inhibiting the HER2 signaling pathway, which is the main driver of cancer cell proliferation and progression for this breast cancer subtype[6]. This evidence concerns the gene ERBB2 and breast carcinoma.